Join Next LSI Event

Join Now

LSI Europe '24 Summit

Filling Fast

Global Opportunities in the Interventional Management of Symptomatic Peripheral Artery Disease

Published January 2015 | 200 Pages | 75 Exhibits | Forecasts Through 2019

Order individually or subscribe to Medtech Pro and get a complete intel platform.

Overview

This report covers the novel drug-coated balloon and drug-eluting stent technologies that are expected to trigger a paradigm shift in treatment of advanced peripheral artery disease-particularly lower extremity occlusions-driving the development of a new multi-billion dollar market. Also covered in the report are revascularization-enabling peripheral atherectomy systems and dedicated refractory CTO crossing devices that are projected to see above-average growth through 2019.

Companies Covered

Aachen Resonance

Abbott Vascular (Abbott Laboratories) 

Avinger Medical Technologies

Bard Peripheral (C.R. Bard)

Bayer HealthCare (Bayer AG)

Biosensors International

Biotronik 

Boston Scientific

Cardionovum

Cardiovascular Systems 

Cook Medical

Cordis (Johnson & Johnson)

Covidien

Eurocor (Opto Circuits) 

iVascular 

Medtronic

Medtronic plc 

Spectranetics

Table of Contents

EXECUTIVE SUMMARY 

Symptomatic Peripheral Artery Disease

Interventions by Major Type 

Global Product Markets 

Product Markets by Major Geography 

Major Suppliers

 

Summary Exhibit 1: Estimated Prevalence of Symptomatic Peripheral Artery Disease by Major Geography, 2013-2019 

Summary Exhibit 2: Peripheral Angioplasty Procedures by Major Geography, 2013 – 2019 

Summary Exhibit 3: Distribution of Global PTA Procedures by Lesion Location and Major Procedure Type, 2013-2019 

Summary Exhibit 4: Global Market for Targeted Devices by Type, 2013-2019

Summary Exhibit 5: Global Market for Four Targeted Products by Major Geography, 2013-2019

Summary Exhibit 6: Global Market for Peripheral Drug-Coated Balloons by Major Geography, 2013-2019

Summary Exhibit 7: Global Market for Peripheral Drug-Eluting Stents by Major Geography, 2013-2019

Summary Exhibit 8: Global Market for Peripheral Atherectomy Devices, 2013-2019 

Summary Exhibit 9: Global Market for Dedicated Refractory CTO Devices, 2013-2019 

Summary Exhibit 10: Market for Four Targeted Products, United States, 2013-2019

Summary Exhibit 11: Market for Four Targeted Products, Major Europe, 2013-2019

Summary Exhibit 12: Market for Four Targeted Products, Major Asia-Pacific, 2013-2019

Summary Exhibit 13: Market for Four Targeted Products, Rest of World, 2013-2019

Summary Exhibit 14: Leading Suppliers of Four Targeted Products, 2014 

 

1.0 ETIOLOGY, EPIDEMIOLOGY & PROCEDURES 

1.1 Overview of Peripheral Vascular Infrastructure 

1.2 Peripheral Arterial Disease 

1.2.1 Symptoms 

1.2.2 Causes 

1.2.3 Risk Factors 

1.2.4 Prevalence

1.3 Critical Limb Ischemia 

1.3.1 Causes 

1.3.2 Disease Progression 

1.3.3 Disease Management and Interventional Therapy

1.3.4 Incidence of CLI and Limb Amputation

1.4 Chronic Total Occlusions 

1.4.1 Incidence 

1.4.2 Treatment Regimens 

1.5 PTA Procedures 

1.5.1 Peripheral Angioplasties by Location

1.5.2 Peripheral Angioplasties by Type

 

Exhibit 1-1: Major Lower Extremity Arteries 

Exhibit 1-2: Normal versus Atherosclerotic Peripheral Artery

Exhibit 1-3: Estimated Prevalence of Symptomatic Peripheral Artery Disease by Major Geography, 2013-2019

Exhibit 1-4: Overview of Peripheral Artery Disease and Critical Limb Ischemia 

Exhibit 1-5: Estimated Incidence of Critical Limb Ischemia and Limb Amputation by Selected Geographies, 2013-2019 

Exhibit 1-6: Development of a Chronic Total Occlusion 

Exhibit 1-7: Peripheral Angioplasty Procedures by Major Geography, 2013–2019 

Exhibit 1-8: Distribution of PTA Procedures by Lesion Location, United States, 2013-2019

Exhibit 1-9: Distribution of PTA Procedures by Lesion Location, Major Europe, 2013-2019

Exhibit 1-10: Distribution of PTA Procedures by Lesion Location, Major Asia-Pacific, 2013-2019

Exhibit 1-11: Distribution of PTA Procedures by Lesion Location, Rest of World, 2013-2019

Exhibit 1-12: Distribution of Global PTA Procedures by Lesion Location, 2013-2019 

Exhibit 1-13: Distribution of PTA Procedures by Type, United States, 2013-2019 

Exhibit 1-14: Distribution of PTA Procedures by Type, Major Europe, 2013-2019 

Exhibit 1-15: Distribution of PTA Procedures by Type, Major Asia-Pacific, 2013-2019 

Exhibit 1-16: Distribution of PTA Procedures by Type, Rest of World, 2013-2019 

Exhibit 1-17: Distribution of Global PTA Procedures by Type, 2013-2019

 

2.0 PRODUCTS AND TECHNOLOGIES 

2.1 Peripheral Drug-Coated Balloons

2.1.1 Drug Delivery Methods 

2.1.2 Balloon Coating Technologies

2.1.3 Carrier Excipients 

2.1.4 Products

2.1.4.1 Aachen Resonance

2.1.4.2 Bard Peripheral Vascular 

2.1.4.3 Bayer AG

2.1.4.4 Biotronik 

2.1.4.5 Biosensors International

2.1.4.6 Boston Scientific

2.1.4.7 Cardionovum

2.1.4.8 Cook Medical

2.1.4.9 Eurocor

2.1.4.10 iVascular 

2.1.4.11 Medtronic plc 

2.1.4.12 Spectranetics 

2.1.5 Second Generation DCB Technologies under Development

2.1.6 Clinical Experience with Drug-Coated Balloons

2.2 Peripheral Drug-Eluting Stents 

2.2.1 Anti-Restenosis Drugs 

2.2.2 Products

2.2.2.1 Abbott Vascular 

2.2.2.2 Alvimedica Medical Technologies 

2.2.2.3 Boston Scientific

2.2.2.4 Cook Medical

2.2.2.5 Johnson & Johnson Cordis

2.2.3 Clinical Experience with Peripheral DES

2.2.3.1 SIROCCO I and II 

2.2.3.2 Zilver PTX Trial 

2.2.3.3 ACHILLES Trial 

2.2.3.4 DESTINY Trial

2.3 Peripheral Debulking Technologies

2.3.1 Atherectomy Systems 

2.3.2 Atherotomy Devices 

2.4 Dedicated Refractory CTO Crossing Devices 

2.4.1 Products

2.4.2 Clinical Experience

 

Exhibit 2-1: Selected Peripheral Drug-Coated Balloon (DCB) Angioplasty Systems, 2015

Exhibit 2-2: Performance Data from Clinical Trials of Drug-Coated Balloons versus PTA in Symptomatic Patients with Superficial Femoral Artery (SFA) Occlusiions 

Exhibit 2-3: Performance Data from Clinical Trials of Drug-Coated Balloons versus Peripheral Transluminal Angioplasty in Symptomatic Critical Limb Ischemia Patients with Below-the-Knee Arterial Occlusions 

Exhibit 2-4: Selected Peripheral Drug-Eluting Stent Technologies, 2015 

Exhibit 2-5: Performance Data from Clinical Trials of Drug-Coated Stents versus Control in Patients with Symptomatic Critical Limb Ischemia and Superficial Femoral Artery (SFA) and Below-the-Knee (BTK) Occlusions

Exhibit 2-6: Overview of Peripheral Debulking Technologies

Exhibit 2-7: Selected Peripheral Atherectomy Technologies, 2015 

Exhibit 2-8: Selected Atherotomy Technologies, 2015 

Exhibit 2-9: Selected Crossing Support Catheters, 2015 

Exhibit 2-10: Selected Dedicated Refractory CTO Devices, 2015

Exhibit 2-11: Selected Trials of Dedicated Peripheral Refractory CTO Technologies

 

3.0 PROCEDURES & MARKETS 

3.1 Drug-Coated Balloons 

3.1.1 Procedures and Markets by Geography 

3.1.2 Competitive Analysis

3.2 Drug-Eluting Stents 

3.2.1 Procedures and Markets by Geography 

3.2.2 Competitive Analysis

3.3 Atherectomy Devices

3.3.1 Procedures and Markets by Geography 

3.3.2 Competitive Analysis

3.4 Dedicated Refractory CTO Crossing Devices 

3.4.1 Procedures and Markets by Geography 

3.4.2 Competitive Analysis

 

Exhibit 3-1: Global Peripheral Drug-Coated Balloon , Procedures and Market, 2013-2019

Exhibit 3-2: Peripheral Drug-Coated Balloon Angioplasty, United States, Procedures and Market, 2013-2019 

Exhibit 3-3: Peripheral Drug-Coated Balloon Angioplasty, Major Europe, Procedures and Market, 2013-2019 

Exhibit 3-4: Peripheral Drug-Coated Balloon Angioplasty, Major Asia-Pacific, Procedures and Market, 2013-2019 

Exhibit 3-5: Peripheral Drug-Coated Balloon Angioplasty, Rest of World, Procedures and Market, 2013-2019 

Exhibit 3-6: Peripheral Drug-Coated Balloons, Estimated Supplier Shares, 2014

Exhibit 3-7: Global Peripheral Drug-Eluting Stents, Procedures and Markets, 2013-2019

Exhibit 3-8: Peripheral Drug-Eluting Stents, United States, Procedures and Markets, 2013-2019

Exhibit 3-9: Peripheral Drug-Eluting Stents, Major Europe, Procedures and Markets, 2013-2019

Exhibit 3-10: Peripheral Drug-Eluting Stents, Major Asia-Pacific, Procedures and Markets, 2013-2019

Exhibit 3-11: Peripheral Drug-Eluting Stents, Rest of World, Procedures and Markets, 2013-2019

Exhibit 3-12: Peripheral Dug-Eluting Stents, Estimated Supplier Shares, 2014

Exhibit 3-13: Global Peripheral Atherectomy, Procedures and Markets, 2013-2019 

Exhibit 3-14: Peripheral Atherectomy, United States, Procedures and Markets, 2013-2019

Exhibit 3-15: Peripheral Atherectomy, Major Europe, Procedures and Markets, 2013-2019

Exhibit 3-16: Peripheral Atherectomy, Major Asia-Pacific, Procedures and Markets, 2013-2019

Exhibit 3-17: Peripheral Atherectomy, Rest of World, Procedures and Markets, 2013-2019

Exhibit 3-18: Peripheral Atherectomy, Estimated Supplier Shares, 2014

Exhibit 3-19: Global Peripheral Refractory CTO Crossing, Procedures and Markets, 2013-2019

Exhibit 3-20: Peripheral Refractory CTO Crossing, United States, Procedures and Markets, 2013-2019

Exhibit 3-21: Peripheral Refractory CTO Crossing, Major Europe, Procedures and Markets, 2013-2019

Exhibit 3-22: Peripheral Refractory CTO Crossing, Major Asia-Pacific, Procedures and Markets, 2013-2019

Exhibit 3-23: Peripheral Refractory CTO Crossing, Rest of World, Procedures and Markets, 2013-2019

Exhibit 3-24: Dedicated Peripheral CTO Crossing Devices, Supplier Shares, 2014

 

4.0 COMPANY PROFILES

4.1 Aachen Resonance

4.2 Abbott Vascular (Abbott Laboratories) 

4.3 Avinger Medical Technologies

4.4 Bard Peripheral (C.R. Bard)

4.5 Bayer HealthCare (Bayer AG)

4.6 Biosensors International

4.7 Biotronik 

4.8 Boston Scientific

4.9 Cardionovum

4.10 Cardiovascular Systems 

4.11 Cook Medical

4.12 Cordis (Johnson & Johnson)

4.13 Eurocor (Opto Circuits) 

4.14 iVascular 

4.15 Medtronic plc 

4.15.1 Covidien

4.15.2 Medtronic

4.16 Spectranetics 

 

5.0 MAJOR COUNTRY PROFILES

5.1 United States 

5.2 Major Western Europe

5.2.1 Overview of European Healthcare

5.2.1.1 Healthcare Spending and Reforms

5.2.1.2 Healthcare Facilities and Manpower 

5.2.1.3 Reimbursement 

5.2.1.4 Impact of the European Union

5.2.2 National Healthcare Profiles 

5.2.2.1 France

5.2.2.2 Germany

5.2.2.3 Italy 

5.2.2.4 Spain 

1.2.2.5 United Kingdom

5.3 Major Asia-Pacific 

5.3.1 China

5.3.2 India 

5.3.3 Japan 

 

Exhibit 5-1: United States, Selected Health Care Indicators 

Exhibit 5-2: France, Selected Health Care Indicators

Exhibit 5-3: Germany, Selected Health Care Indicators

Exhibit 5-4: Italy, Selected Health Care Indicators 

Exhibit 5-5: Spain, Selected Health Care Indicators

Exhibit 5-6: United Kingdom, Selected Health Care Indicators

Exhibit 5-7: China, Selected Health Care Indicators 

Exhibit 5-8: India, Selected Health Care Indicators

Exhibit 5-9: Japan, Selected Health Care Indicators

 

Companies We Work With